Literature DB >> 17090611

Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia.

Olga W Souverein1, Joep C Defesche, Aeilko H Zwinderman, John J P Kastelein, Michael W T Tanck.   

Abstract

AIMS: To investigate the influence of different LDL-receptor (LDLR) gene mutations on age at first cardiovascular event in familial hypercholesterolaemia (FH) patients. METHODS AND
RESULTS: Dutch FH patients (n = 862) with known LDLR mutations from a retrospective cohort study were included. A gamma frailty Cox model was used. An event was defined as the first cardiovascular event. Gender, hypertension, smoking, diabetes, HDL cholesterol, LDL cholesterol (LDL-C), or triglycerides were included as covariates. Furthermore, the effect of LDLR mutation type on LDL and HDL cholesterol levels was investigated using mixed effects models, including gender, smoking, body mass index, and age at time of lipid measurement as covariates. A total of 86 different LDLR mutations were present in this cohort. Twenty-two percent of patients experienced an event (median age: 47.1 year; range: 25.6-85.8 years). The effect of LDLR mutation type on event-free survival is only significant in the models without LDL-C levels. Also, LDLR mutation type was significantly associated with LDL-C levels (P = 0.007), but not with HDL cholesterol levels (P = 0.12).
CONCLUSION: In the present study, LDL-C levels are a more important risk factor of event-free survival than the type of LDLR mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090611     DOI: 10.1093/eurheartj/ehl366

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  New contributions to the study of common double mutants in the human LDL receptor gene.

Authors:  M Teresa Tejedor; Ana Cenarro; Diego Tejedor; Marianne Stef; Lourdes Palacios; Isabel de Castro; Angel L García-Otín; Luis V Monteagudo; Fernando Civeira; Miguel Pocovi
Journal:  Naturwissenschaften       Date:  2011-09-21

2.  A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with Familial Hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.

Authors:  Karen Broekhuizen; Mireille N M van Poppel; Lando L J Koppes; Johannes Brug; Willem van Mechelen
Journal:  BMC Public Health       Date:  2010-02-15       Impact factor: 3.295

3.  Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Authors:  Roeland Huijgen; Iris Kindt; Sjoerd B J Verhoeven; Eric J G Sijbrands; Maud N Vissers; John J P Kastelein; Barbara A Hutten
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

4.  Cascade Screening for Familial Hypercholesterolemia (FH).

Authors:  Renée M Ned; Eric J G Sijbrands
Journal:  PLoS Curr       Date:  2011-05-23

5.  Common genetic variants do not associate with CAD in familial hypercholesterolemia.

Authors:  Erik P A van Iperen; Suthesh Sivapalaratnam; S Matthijs Boekholdt; G Kees Hovingh; Stephanie Maiwald; Michael W Tanck; Nicole Soranzo; Jonathan C Stephens; Jennifer G Sambrook; Marcel Levi; Willem H Ouwehand; John Jp Kastelein; Mieke D Trip; Aeilko H Zwinderman
Journal:  Eur J Hum Genet       Date:  2013-11-13       Impact factor: 4.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.